Product Pipeline
| Product | Indication | Late Research | Pre-clinical | Phase I | Phase II | Phase III | Market | Marketing Rights |
|---|---|---|---|---|---|---|---|---|
 |
||||||||
| Priority Programmes |  |
|||||||
|
||||||||
| V3381 | Neuropathic Pain |  |
World Wide |
|||||
|
||||||||
| V2006 | Parkinson’s Disease | |
Biogen Idec | |||||
|
||||||||
| V85546 | Inflammatory Disease |
 |
Worldwide | |||||
|
||||||||
| NVP-AUY922 | Cancer | |
Novartis (Milestone & Royalties) |
|||||
|
||||||||
| NVP-HSP990 (oral) | Cancer | |
Novartis (Milestone & Royalties) |
|||||
|
||||||||
| V158866 (FAAH) | Pain |  |
Worldwide | |||||
|
||||||||
| V158411 (Chk1) | Cancer | |
Worldwide | |||||
|
||||||||
| Progress through partnering | |
|||||||
|
||||||||
| V1512 | Parkinson’s Disease |  |
World Wide (excl. Italy) |
|||||
|
||||||||
| V10153 | Ischaemic stroke | |
World Wide | |||||
|
||||||||